Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Renata FerrarottoMoran AmitPriyardhisini NagarajanM Laura RubinYing YuanDiana BellAdel K El-NaggarJason M JohnsonWilliam H MorrisonDavid I RosenthalBonnie S GlissonFaye M JohnsonCharles LuFrank E MottBita EsmaeliEduardo M DiazPaul W GidleyRyan P GoepfertCarol M LewisRandal S WeberJennifer A WargoSreyashi BasuFei DuanShalini Singh YadavPadmanee SharmaJames P AllisonJeffrey N MyersNeil D GrossPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Neoadjuvant immunotherapy in locoregionally advanced, resectable CSCC-HN is safe and induces a high pathologic response rate. Pathologic responses were associated with an inflamed tumor microenvironment.